Sana Biotechnology Reports 14-Month Success in Immune-Evasive Islet Cell Therapy for Type 1 Diabetes

A potential breakthrough in the treatment of Type 1 diabetes (T1D) is emerging as Sana Biotechnology shares long-term clinical data from its first-in-human study. The company has revealed that a single patient receiving a specialized islet cell transplant continued to produce insulin for 14 months without the need for lifelong immunosuppressive drugs—a hurdle that has long hindered the success of cell-based therapies.

Understanding the UP421 Therapy

The treatment, known as UP421, is a donor-derived primary islet cell therapy. In a healthy body, islet cells in the pancreas produce insulin to regulate blood sugar. In people with Type 1 diabetes, the immune system attacks these cells, leading to insulin deficiency.

Sana’s approach involves gene-editing these donor cells to develop them “hypoimmune” (HIP). This modification is designed to allow the transplanted cells to hide from the recipient’s immune system, effectively preventing rejection without requiring the patient to capture toxic immunosuppressant medications. In this study, the cells were transplanted into the patient’s arm.

Clinical Results: 14-Month Follow-Up

According to a March 13, 2026, release, the therapy demonstrated “sustained survival and function of pancreatic beta cells.”

C-Peptide and Insulin Production

Researchers monitored C-peptide, a biomarker that indicates whether transplanted beta cells are producing insulin. The findings included:

• Meal Response: C-peptide levels rose during a mixed meal tolerance test (MMTT), which aligns with how a healthy body secretes insulin in response to food.
• Stability: Fasting and MMTT-stimulated C-peptide levels at month 14 were similar to those recorded during the first six months.
• Recovery: Whereas C-peptide levels temporarily declined around the one-year mark—likely due to beta cell exhaustion—they subsequently recovered, suggesting the cells can regain function.

Glycemic Control and Safety

Data presented at the Advanced Technologies & Treatments for Diabetes (ATTD) conference indicated that the patient experienced tighter glycemic control between months 12 and 14. Dr. Per-Ola Carlsson, the Study Principal Investigator, noted that these results demonstrate the positive impact of improved glucose control on the dynamic functional capacity of the transplanted beta cells.

The Path Forward: From Donor Cells to Stem Cells

While the UP421 study used donor-derived cells, Sana Biotechnology is also advancing SC451, a HIP-modified stem cell-derived islet cell therapy. The company expects to begin a phase I trial for SC451 as early as 2026, moving toward a more scalable source of cells for T1D treatment.

Frequently Asked Questions

What is a “functional cure” for diabetes?

A functional cure refers to a treatment that allows the body to regulate blood glucose levels independently—through the production of insulin by transplanted or regenerated cells—reducing or eliminating the need for external insulin injections.

Why is avoiding immunosuppression essential?

Traditional transplants require lifelong immunosuppressant drugs to prevent the body from rejecting the latest organ or cells. These drugs can have severe side effects, including increased susceptibility to infections and other systemic health issues.

Is this therapy available to the public?

No. These results are from an early-stage, first-in-human clinical trial involving a single participant. Further large-scale studies are required to confirm these findings before the therapy can be approved for general use.

Conclusion

The 14-month data from Sana Biotechnology provides a critical proof of concept: gene-edited, immune-evasive islet cells can survive and function in a human with Type 1 diabetes without the need for immunosuppressants. If these results are replicated in larger cohorts, it could transform the landscape of diabetes care, moving the field closer to a scalable, long-term cure.